CompletedNot Applicable

Predictive Role of KLK10 and Other Neuroinflammatory Molecules on Clinical Outcomes of AIS

China273 participantsStarted 2024-08-12

Plain-language summary

This study aims to investigate the dynamic changes and differential expression characteristics of neuroinflammatory molecules such as kallikrein-related peptidase 10 (KLK10), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), and glial fibrillary acidic protein (GFAP) in the plasma of patients with first-ever anterior circulation acute ischemic stroke (AIS). It will analyze the correlation between these molecules and the severity of neurological deficits, infarct volume, brain edema, hemorrhagic transformation, progressive stroke, and clinical outcomes at three months. The goal is to assess the predictive value of these molecules for AIS prognosis, guiding early treatment and new molecular targets for prevention and treatment.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: for AIS patients: * Selection of 182 patients with first-ever acute ischemic stroke (AIS) who are hospitalized at our hospital, aged ≥18 years, with no restriction on gender; * Patients must be admitted within 24 hours of the onset of AIS; * Diagnosis must be confirmed by cranial magnetic resonance imaging (MRI) or computed tomography (CT); * All enrolled patients must provide written informed consent. for healthy controls: * Age and gender-matched; * No organic diseases; * Written informed consent must be signed Exclusion Criteria: * Intracranial hemorrhage; * Pregnancy; * Stroke with unknown onset time; * Malignant tumors; * Hematologic disorders; * Severe liver or kidney dysfunction; * Recent myocardial infarction (less than 3 months); * Ongoing anti-inflammatory drug treatment.

What they're measuring

the Modified Rankin Scale (mRS) score

Timeframe: Record the Modified Rankin Scale (mRS) score at 3 months after stroke onset

Trial details

NCT IDNCT06549972

SponsorRuijin Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-06-30

View on ClinicalTrials.gov More Ischemic Stroke trials

Plain-language summary

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.